Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eric Bergeron is active.

Publication


Featured researches published by Eric Bergeron.


Journal of Biological Chemistry | 2008

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.

Steve Poirier; Gaétan Mayer; Suzanne Benjannet; Eric Bergeron; Jadwiga Marcinkiewicz; Nasha Nassoury; Harald Mayer; Johannes Nimpf; Annik Prat; Nabil G. Seidah

The proprotein convertase PCSK9 gene is the third locus implicated in familial hypercholesterolemia, emphasizing its role in cardiovascular diseases. Loss of function mutations and gene disruption of PCSK9 resulted in a higher clearance of plasma low density lipoprotein cholesterol, likely due to a reduced degradation of the liver low density lipoprotein receptor (LDLR). In this study, we show that two of the closest family members to LDLR are also PCSK9 targets. These include the very low density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 (ApoER2) implicated in neuronal development and lipid metabolism. Our results show that wild type PCSK9 and more so its natural gain of function mutant D374Y can efficiently degrade the LDLR, VLDLR, and ApoER2 either following cellular co-expression or re-internalization of secreted human PCSK9. Such PCSK9-induced degradation does not require its catalytic activity. Membrane-bound PCSK9 chimeras enhanced the intracellular targeting of PCSK9 to late endosomes/lysosomes and resulted in a much more efficient degradation of the three receptors. We also demonstrate that the activity of PCSK9 and its binding affinity on VLDLR and ApoER2 does not depend on the presence of LDLR. Finally, in situ hybridization show close localization of PCSK9 mRNA expression to that of VLDLR in mouse postnatal day 1 cerebellum. Thus, this study demonstrates a more general effect of PCSK9 on the degradation of the LDLR family that emphasizes its major role in cholesterol and lipid homeostasis as well as brain development.


Cytokine & Growth Factor Reviews | 2009

Cell responses to bone morphogenetic proteins and peptides derived from them: Biomedical applications and limitations

Helena Senta; Park H; Eric Bergeron; Olivier Drevelle; D. Fong; Élisabeth Leblanc; François Cabana; Sophie Roux; Guillaume Grenier; Nathalie Faucheux

The bone morphogenetic proteins (BMPs) are cytokines of the transforming growth factor beta family. Some BMPs such as BMP-2 and BMP-7 play a major role in the development of the skeleton and the maintenance of homeostasis during bone remodelling. To date, only BMP-2 and BMP-7 have been approved by the Food and Drug Administration for specific orthopaedic applications. However, due to BMP cost, peptides derived from their knuckle epitope with osteogenic properties have been developed. BMPs are involved in many other biological events, including embryogenesis, angiogenesis and cancer. BMPs therefore have great biomedical potential as osteogenic factors and as anti-cancer agents. This review focuses on the use of BMPs and their derived peptides in biomedical delivery systems and gene therapy.


Journal of Virology | 2010

Crimean-Congo Hemorrhagic Fever Virus-Encoded Ovarian Tumor Protease Activity Is Dispensable for Virus RNA Polymerase Function

Eric Bergeron; César G. Albariño; Marina L. Khristova; Stuart T. Nichol

ABSTRACT Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus (genus Nairovirus, family Bunyaviridae) associated with high case fatality disease outbreaks in regions of Africa, Europe, and Asia. The CCHFV genome consists of three negative-strand RNA segments, S, M, and L. The unusually large virus L polymerase protein and the need for biosafety level 4 (BSL-4) containment conditions for work with infectious virus have hampered the study of CCHFV replication. The L protein has an ovarian tumor (OTU) protease domain located in the N terminus, which has led to speculation that the protein may be autoproteolytically cleaved to generate the active virus L polymerase and additional functions. We report the successful development of efficient CCHFV helper virus-independent S, M, and L segment minigenome systems for analysis of virus RNA and protein features involved in replication. The virus RNA segment S, M, and L untranslated regions were found to be similar in support of replication of the respective minigenomes. In addition, the OTU domain located in the N terminus of the expressed virus L protein was shown to be a functional protease. However, no evidence of L protein autoproteolytic processing was found, and the OTU protease activity was dispensable for virus RNA replication. Finally, physiologically relevant doses of ribavirin inhibited CCHFV minigenome replication. These results demonstrated the utility of the minigenome system for use in BSL-2 laboratory settings to analyze CCHFV biology and in antiviral drug discovery programs for this important public health and bioterrorism threat.


Journal of Bone and Mineral Research | 2011

BMP‐9‐induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment

Élisabeth Leblanc; Frédéric Trensz; Sonia Haroun; Geneviève Drouin; Eric Bergeron; Christopher M Penton; Federica Montanaro; Sophie Roux; Nathalie Faucheux; Guillaume Grenier

Heterotopic ossification (HO) is defined as the formation of bone inside soft tissue. Symptoms include joint stiffness, swelling, and pain. Apart from the inherited form, the common traumatic form generally occurs at sites of injury in damaged muscles and is often associated with brain injury. We investigated bone morphogenetic protein 9 (BMP‐9), which possesses a strong osteoinductive capacity, for its involvement in muscle HO physiopathology. We found that BMP‐9 had an osteoinductive influence on mouse muscle resident stromal cells by increasing their alkaline phosphatase activity and bone‐specific marker expression. Interestingly, BMP‐9 induced HO only in damaged muscle, whereas BMP‐2 promoted HO in skeletal muscle regardless of its state. The addition of the soluble form of the ALK1 protein (the BMP‐9 receptor) significantly inhibited the osteoinductive potential of BMP‐9 in cells and HO in damaged muscles. BMP‐9 thus should be considered a candidate for involvement in HO physiopathology, with its activity depending on the skeletal muscle microenvironment.


Journal of Virology | 2007

Crimean-Congo Hemorrhagic Fever Virus Glycoprotein Processing by the Endoprotease SKI-1/S1P Is Critical for Virus Infectivity

Eric Bergeron; Martin J. Vincent; Stuart T. Nichol

ABSTRACT Crimean-Congo hemorrhagic fever virus (CCHFV) causes severe human disease. The CCHFV medium RNA encodes a polyprotein which is proteolytically processed to yield the glycoprotein precursors PreGn and PreGc, followed by structural glycoproteins Gn and Gc. Subtilisin kexin isozyme-1/site-1 protease (SKI-1/S1P) plays a central role in Gn processing. Here we show that CCHFV-infected cells deficient in SKI-1/S1P produce no infectious virus, although PreGn and PreGc accumulated normally in the Golgi apparatus, the site of virus assembly. Only nucleoprotein-containing particles which lacked virus glycoproteins (Gn/Gc or PreGn/PreGc) were secreted. Complementation of SKI-1/S1P-deficient cells with a SKI-1/S1P expression vector restored release of infectious virus (>106 PFU/ml), confirming that SKI-1/S1P processing is required for incorporation of viral glycoproteins. SKI-1/S1P may represent a promising antiviral target.


Biochemical and Biophysical Research Communications | 2005

Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus.

Eric Bergeron; Martin J. Vincent; Louise Wickham; Josée Hamelin; Ajoy Basak; Stuart T. Nichol; Michel Chrétien; Nabil G. Seidah

Abstract Severe acute respiratory syndrome coronavirus (SARS-CoV) is the etiological agent of SARS. Analysis of SARS-CoV spike glycoprotein (S) using recombinant plasmid and virus infections demonstrated that the S-precursor (proS) exists as a ∼190kDa endoplasmic reticulum form and a ∼210kDa Golgi-modified form. ProS is subsequently processed into two C-terminal proteins of ∼110 and ∼80kDa. The membrane-bound proprotein convertases (PCs) furin, PC7 or PC5B enhanced the production of the ∼80kDa protein. In agreement, proS processing, cytopathic effects, and viral titers were enhanced in recombinant Vero E6 cells overexpressing furin, PC7 or PC5B. The convertase inhibitor dec-RVKR-cmk significantly reduced proS cleavage and viral titers of SARS-CoV infected cells. In addition, inhibition of processing by dec-RVKR-cmk completely abrogated the virus-induced cellular cytopathicity. A fluorogenically quenched synthetic peptide encompassing Arg761 of the spike glycoprotein was efficiently cleaved by furin and the cleavage was inhibited by EDTA and dec-RVKR-cmk. Taken together, our data indicate that furin or PC-mediated processing plays a critical role in SARS-CoV spread and cytopathicity, and inhibitors of the PCs represent potential therapeutic anti-SARS-CoV agents.


Journal of Controlled Release | 2012

Bone repair: new developments in growth factor delivery systems and their mathematical modeling.

Marc-Antoine Lauzon; Eric Bergeron; Bernard Marcos; Nathalie Faucheux

More and more of our aging populations will suffer from large bone defects in the next few years. But the growth factor (GF) delivery systems (DSs) currently under investigation will help overcome the limitations of the bone grafts presently used. Some GFDSs accredited by the Food and Drug Administration (FDA) are commercially available, but they have mechanical, structural and GF retention weaknesses. New studies focus on polymers and the composition of GFs in order to mimic as closely as possible the physiological environment of healing bone. This review first summarizes the process of endochondral bone healing and the major cytokines involved. We then review the latest GFDSs, with their combinations of organic, inorganic, natural and synthetic biomaterials, the kinetics of GF release and their biological effects. We will explore new research avenues such as the use of peptides derived from bone morphogenetic proteins, including our own results, and the sequential release of bone-inducing GFs. We then review the latest mathematical models of drug delivery systems (DDSs) for several transport phenomena that may be encountered when using GFDS. The final section discusses new improvements for GFDS modeling.


Frontiers in Bioscience | 2009

Bone cells-biomaterials interactions.

Marquis Me; Lord E; Eric Bergeron; Olivier Drevelle; Park H; François Cabana; Helena Senta; Nathalie Faucheux

With the aging population, the incidence of bone defects due to fractures, tumors and infection will increase. Therefore, bone replacement will become an ever bigger and more costly problem. The current standard for bone replacement is autograft, because these transplants are osteoconductive and osteoinductive. However, harvesting an autograft requires additional surgery at the donor site that is related to high level of morbidity. In addition, the quantity of bone tissue that can be harvested is limited. These limitations have necessitated the pursuit of alternatives using biomaterials. The control of bone tissue cell adhesion to biomaterials is an important requirement for the successful incorporation of implants or the colonization of scaffolds for tissue repair. Controlling cells-biomaterials interactions appears of prime importance to influence subsequent biological processes such as cell proliferation and differentiation. Therefore, interactions of cells with biomaterials have been widely studied especially on two-dimensional systems. This review focuses on these interactions.


Biochemical and Biophysical Research Communications | 2010

Sanguinarine induces apoptosis of human osteosarcoma cells through the extrinsic and intrinsic pathways.

Hyunjin Park; Eric Bergeron; Helena Senta; Kim Guillemette; Sabrina Beauvais; Richard Blouin; Joël Sirois; Nathalie Faucheux

The quaternary benzo[c]phenanthridine alkaloid sanguinarine inhibits the proliferation of cancerous cells from different origins, including lung, breast, pancreatic and colon, but nothing is known of its effects on osteosarcoma, a primary malignant bone tumour. We have found that sanguinarine alters the morphology and reduces the viability of MG-63 and SaOS-2 human osteosarcoma cell lines in concentration- and time-dependent manner. Incubation with 1 micromol/L sanguinarine for 4 and 24h killed more efficiently MG-63 cells than SaOS-2 cells, while incubation with 5 micromol/L sanguinarine killed almost 100% of both cell populations within 24h. This treatment also changed the mitochondrial membrane potential in both MG-63 and SaOS-2 cells within 1h, caused chromatin condensation and the formation of apoptotic bodies. It activated multicaspases, and increased the activities of caspase-8 and caspase-9 in both MG-63 and SaOS-2 cells. These data highlight sanguinarine as a novel potential agent for bone cancer therapy.


The Journal of Infectious Diseases | 2015

Ebola Virus Diagnostics: The US Centers for Disease Control and Prevention Laboratory in Sierra Leone, August 2014 to March 2015

Mike Flint; Christin H. Goodman; Scott W. Bearden; Dianna M. Blau; Brian R. Amman; Alison J. Basile; Jessica A. Belser; Eric Bergeron; Michael D. Bowen; Aaron C. Brault; Shelley Campbell; Ayan K. Chakrabarti; Kimberly A. Dodd; Bobbie R. Erickson; Molly M. Freeman; Aridth Gibbons; Lisa Wiggleton Guerrero; John D. Klena; R. Ryan Lash; Michael K. Lo; Laura K. McMullan; Gbetuwa Momoh; James L. Massally; Augustine Goba; Christopher D. Paddock; Rachael A. Priestley; Meredith Pyle; Mark Rayfield; Brandy J. Russell; Johanna S. Salzer

In August 2014, the Viral Special Pathogens Branch of the US Centers for Disease Control and Prevention established a field laboratory in Sierra Leone in response to the ongoing Ebola virus outbreak. Through March 2015, this laboratory tested >12 000 specimens from throughout Sierra Leone. We describe the organization and procedures of the laboratory located in Bo, Sierra Leone.

Collaboration


Dive into the Eric Bergeron's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Helena Senta

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hyunjin Park

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Etienne Lord

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sophie Roux

Université de Sherbrooke

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aaron C. Brault

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge